The efficacy of EPA on the clinical outcome in patients with arteriosclerosis obliterans undergoing endvascular treatment: Prospective study

The efficacy of EPA on the clinical outcome in patients with arteriosclerosis obliterans undergoing endvascular treatment: Prospective study - arteriosclerosis obliterans and EPA

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026607

Enrollment

300

Registered

2017-03-18

Start date

2014-09-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

arteriosclerosis obliterans

Interventions

Medication: EPA 1800mg/day, Duration: 2 years Contrcol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with arteriosclerosis obliterans EPA/AA ratio<0.4 Patients who agree to take an informed consent

Exclusion criteria

Exclusion criteria: Patients with aortic diseae, BK disease, otherresidual vascular disease, formely taking EPA,EVT failure,use of DES,and contraindication of EPA.

Design outcomes

Primary

Measure	Time frame
Major lower limbs events(revascularization, amputation)	—

Secondary

Measure	Time frame
Fontaine classification,Rutherford classification,6MW,ABI(Ankle Brachial Pressure Index),TBI(toe brachial pressure index),SPP(skin perfusion pressure),Major cardiovascular events	—

Countries

Japan

Contacts

Public ContactShunji Yoshikawa

Tokyo Medical and Dental University Department of Cardiovascular medicine

sysh.cvm@tmd.ac.jp03-5803-5231

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026